AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
IT News Online - AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
itnewsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnewsonline.com Daily Mail and Mail on Sunday newspapers.
The U.S. new cases 7-day rolling average are 1.7 % LOWER than the 7-day rolling average one week ago. U.S. hospitalizations due to COVID-19 are now 4.1 %
HIGHER than the rolling average one week ago. U.S. deaths due to coronavirus are now 3.4 %
HIGHER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are at an elevated 228,131
U.S. Coronavirus hospitalizations are at a record 119,463
U.S. Coronavirus deaths are at an elevated 3,359
U.S. Coronavirus immunizations are 9,465,725 doses distributed and 1,008,025 doses administered as of 23 December
The 7-day rolling average rate of growth of the pandemic shows new cases improved, hospitalizations improved, and deaths improved
| Press Release
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers
Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects
OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 Long Hauler portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM s flagship pipeline drug Ampligen.